Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin, Administered Using Stereotactic Injection to the Striatum of Patients With Bilateral, Idiopathic Parkinson's Disease.

Trial Profile

A Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin, Administered Using Stereotactic Injection to the Striatum of Patients With Bilateral, Idiopathic Parkinson's Disease.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Oct 2018

At a glance

  • Drugs AXO Lenti PD (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Oxford BioMedica
  • Most Recent Events

    • 25 Oct 2018 According to an Axovant Sciences media release, updated data from the study has been presented at the Annual Congress of the European Society of Gene and Cell Therapy and published in Human Gene Therapy, Clinical Development.
    • 09 Oct 2018 According to an Oxford BioMedica media release, data from this study to be Presented at the Annual Congress of the European Society.
    • 17 Mar 2017 According to an Oxford BioMedica media release, follow-up data from the study has been presented in May 2016 at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top